Thomas Catinazzo - Sep 8, 2022 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role
Chief Financial Officer
Signature
/s/ Brian Adams, as Attorney-in-Fact
Stock symbol
RLAY
Transactions as of
Sep 8, 2022
Transactions value $
-$679,531
Form type
4
Date filed
9/8/2022, 08:26 PM
Previous filing
Jul 29, 2022
Next filing
Sep 29, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLAY Common Stock Options Exercise $108K +26.3K +50.28% $4.12 78.5K Sep 8, 2022 Direct F1, F2
transaction RLAY Common Stock Sale -$788K -26.3K -33.46% $30.00 52.2K Sep 8, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RLAY Stock Option (Right to Buy) Options Exercise $0 -26.3K -100% $0.00* 0 Sep 8, 2022 Common Stock 26.3K $4.12 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2021.
F2 Includes 45,273 shares underlying restricted stock units.
F3 Twenty-five percent (25%) of the shares underlying this option vested on April 9, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.